OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100

M. Reck,F. Barlesi,J.C.-H. Yang,V. Westeel,E. Felip,M. Özgüroğlu,M. Cobo Dols, R. Sullivan,D. Kowalski,Z. Andric,D.H. Lee,A. Sezer,V. Shamrai,Z. Szalai,X. Wang,H. Xiong,N. Jacob,K. Tadjalli Mehr,K. Park

Journal of Thoracic Oncology（2022）

Cited 0|Views21

No score

Abstract

Avelumab is an anti-PD-L1 antibody that has shown antitumor activity and an acceptable safety profile in patients with non-small cell lung cancer (NSCLC). We report results from the phase 3 JAVELIN Lung 100 trial, which compared first-line (1L) avelumab monotherapy (2 dose schedules) vs platinum-based doublet chemotherapy in patients with previously untreated PD-L1+ advanced NSCLC.

Translated text

Key words

javelin lung,chemotherapy,avelumab,nsclc,first-line

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined